|
Illumina Signs Master Supply Agreement to Provide Next-Generation …
Wall Street Journal “The HLA typing assays we are developing on Illumina’s family of NGS platforms will provide physicians with the ability to more accurately match bone marrow donors to recipients.” “We are excited to support LabCorp’s ability to offer more NGS-based … |
Illumina Shares Hit 52-Week HighZacks.comIllumina is set to enter emerging markets, the third focus area, where it plans to launch a human leukocyte antigen (HLA) typing product in mid-2014. Earlier this month, the company had signed a deal with Quest …
|
Illumina Paves “Roadmap” to NGS Use in Clinical Settings
Genetic Engineering News In emerging markets, Illumina will launch a human leukocyte antigen (HLA) typing product in mid-2014 for laboratories seeking next-generation sequencing on the MiSeq® platform. The product, Illumina asserts, will be faster, less expensive, and more … |
|
Illumina (ILMN) Updates on Road Map at Investor Day
StreetInsider.com (subscription) In emerging markets, Illumina will launch a human leukocyte antigen (HLA) typing product in mid-2014 for laboratories seeking next-generation sequencing on the MiSeq® platform that will be faster, less expensive, and more accurate than current … |
|
Illumina Announces New Organizational Alignment -8K
Benzinga In emerging markets, Illumina will launch a human leukocyte antigen (HLA) typing product in mid-2014 for laboratories seeking next-generation sequencing on the MiSeq® platform that will be faster, less expensive, and more accurate than current … |
|
Illumina Unveils Strategic Roadmap for Market Expansion
Investor’s Business Daily In emerging markets, Illumina will launch a human leukocyte antigen (HLA) typing product in mid-2014 for laboratories seeking next-generation sequencing on the MiSeq® platform that will be faster, less expensive, and more accurate than current … |
Illumina Unveils Strategic Roadmap for Market ExpansionWall Street JournalIllumina is also working in collaboration with the oncology community to develop test guidelines and infrastructure to build actionable cancer genomics solutions. — In emerging …
|
Illumina Unveils Strategic Roadmap for Market Expansion
Business Wire (press release) In emerging markets, Illumina will launch a human leukocyte antigen (HLA) typing product in mid-2014 for laboratories seeking next-generation sequencing on the MiSeq® platform that will be faster, less expensive, and more accurate than current … |
JP Morgan Healthcare Conference, Day Four: Affymetrix, Exact Sciences, FluidigmGenomeWebAg-bio is worth about $95 million, clinical laboratories about $65 million, and HLA typing $25 million, Worthington said. Unlike the single-cell genomics market, wh…
NIPT Continues to Take Off in 2013 as Indications, Insurance Coverage GrowGenomeWeb… estimated total NGS MDx market, by 2015, following by oncology testing, which it predicts to make up about a third of the market, and tests in areas such as infectio…